The medication is commonly used across therapeutic domains where short-term, supportive relief from symptoms related to physical discomfort, inflammation, and fever is applied in therapeutic contexts relevant to adult patients and adolescents over 12 years. Its therapeutic application supports easing symptom burden when manifestations become noticeable and interfere with daily stability. Nam is relevant when supportive symptom management is appropriate for acute pain and primary dysmenorrhoea.

---

Therapeutic Scope and Benefits

This medicine is applied in clinical settings that involve acute or unstable symptom patterns, such as discomfort associated with soft tissue injuries, post-procedural pain, and the cramping lower-abdominal pain of primary dysmenorrhoea. It is also commonly used in conditions where symptoms may intensify temporarily, such as during flare-ups of painful osteoarthritis, to assist with managing pain and stiffness. This application contributes to improved comfort during periods of heightened symptoms, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

“The medication provides supportive relief during symptomatic phases when discomfort and inflammatory signs interfere with routine activities.”

---

Quick Fact: Relief for Acute Discomfort
This medication is used for managing symptoms that appear suddenly (acute pain) and those that are episodic (like menstrual discomfort).

Regulatory References

1. European Medicines Agency assessment

Who can and cannot use Nam? — Official Eligibility Information

Determining eligibility for any prescription medicine requires adherence to official regulatory documents, such as the FDA-approved label or the European Summary of Product Characteristics (SmPC). These documents define the specific patient populations allowed to use the drug and those for whom use is prohibited or restricted.

Eligibility Status	Applicable Populations
Populations for whom use is allowed	Must be determined by a licensed healthcare professional based on the specific indication and patient’s health profile, following the drug’s full prescribing information.
Contraindicated Populations	Individuals with a documented hypersensitivity to the active substance or any of its excipients are typically strictly prohibited from using the medicine. Other clinical conditions may also be listed as formal contraindications.
Age-related Eligibility	Age limits for use are defined by clinical trials and regulatory approval. This often specifies if the medicine is not recommended for children, adolescents, or older adults due to lack of established safety or efficacy data.
Condition-specific Restrictions	Use may be limited or require significant caution in patients with severe hepatic (liver) impairment, renal (kidney) impairment, or specific cardiac conditions, as defined in the official label.
Pregnancy and Lactation Status	The official documentation states whether use during pregnancy or breastfeeding is explicitly contraindicated, not recommended, or requires a formal risk assessment.

All decisions regarding eligibility for Nam must be based on a thorough review of the complete, official prescribing information to ensure safe and effective use. This profile is governed by authoritative health agencies to define the constraints on patient use.

Interactions with other medicines and products

Nam (memantine) has a distinct interaction profile primarily related to its renal elimination and its central nervous system activity. Regulatory agencies emphasize that caution and specific monitoring are required for several drug combinations.

Pharmacokinetic Interactions (Drug Concentration)

Memantine is mainly cleared by the kidneys via a renal cationic transport system. Co-administration with other substances that utilize this system (such as cimetidine, quinidine, ranitidine, or nicotine) may compete with memantine clearance, potentially leading to increased memantine plasma levels.

Furthermore, conditions or medicines that alkalinize the urine (e.g., sodium bicarbonate or severe urinary tract infections) can significantly decrease memantine's urinary elimination, leading to its accumulation in the bloodstream. Conversely, memantine may cause a modest decrease in the bioavailability of hydrochlorothiazide.

Pharmacodynamic Interactions (Additive Effects)

Combinations with other N-methyl-D-aspartate (NMDA) antagonists (e.g., amantadine, ketamine, dextromethorphan) are generally avoided due to the risk of compounded central nervous system (CNS) effects.

The effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced by memantine. Conversely, the effects of barbiturates and neuroleptics may be reduced. Close monitoring of Prothrombin Time or International Normalized Ratio (INR) is advised if memantine is used concomitantly with warfarin.

How Nam Works

---

The molecule functions primarily as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme.

By engaging the COX-2 active site, the drug suppresses the synthesis of powerful pro-inflammatory signals, predominantly **Prostaglandin E2 ( PGE2) from the Arachidonic Acid Cascade. This foundational mechanistic step influences both peripheral signal generation and central thermoregulation. The resulting reduction of PGE2 concentration within the central nervous system (CNS) allows for the normalization of the hypothalamic set-point, while peripheral PGE2 reduction leads to decreased afferent neural input.

Beyond COX-inhibition, the molecule engages in COX-independent actions that modulate the physiological state. These mechanisms include the suppression of tissue-degrading enzymes, such as Matrix Metalloproteinases (MMPs), and the limitation of Reactive Oxygen Species (ROS) generation by immune cells. This secondary domain of action affects cellular and tissue-level processes, contributing to the attenuation of downstream cellular changes and the modulation of the acute inflammatory environment.

How Nam is Used: Official Administration Guidelines

Nimesulide (Nam) is administered according to a strict, time-limited protocol. The medicine is primarily used for systemic relief in the oral form (tablets or granules) and for localized discomfort as a topical gel.

Standard Dosing and Frequency

For systemic use, the standard single dose for adults and adolescents over 12 years of age is 100 mg. This dose is taken twice daily (bid). The maximum permitted daily intake for the systemic formulation is 200 mg. The topical gel is applied locally 2-3 times per day, typically using a ribbon of gel 6 to 7 cm long per application.

Administration Requirements and Duration

The oral dose must be taken after a meal to ensure proper administration. If using the granular form, the contents must be fully dissolved in water before consumption. Nimesulide is restricted to use for the shortest possible duration; the systemic oral course must not exceed 15 days under any circumstances, which reinforces its role as a short-term, acute intervention. The medicine is contraindicated for use in children under 12 years of age.

Procedural Context

If a dose is missed, the patient should skip the missed dose and resume the standard twice-daily schedule with the next planned dose, without taking a double dose. The topical gel should be gently massaged into the affected area until absorbed and must not be used under occlusive dressings or on broken skin. These guidelines delineate the mandatory boundaries of Nimesulide's administration.

Research evidence / Overview of studies for Nam (Nimesulide)

---

Evidence for Use in Acute Pain

Research into Nam was applied in studies examining short-term or episodic symptom patterns related to sudden, acute physical discomfort, such as muscle strains or post-operative pain. This evidence primarily consists of numerous Short-term Randomized Controlled Trials (RCTs). These studies were structured to monitor outcomes related to physical discomfort, often measuring the change in patient-reported scores over defined, brief observation periods. Research examined the time until a measurable change in pain level was reported, with studies documenting the patterns observed after administration.

These findings describe patterns observed in the studies where patients reported changes in outcomes related to physical discomfort over the short follow-up periods. Meta-analyses compiling data from multiple short-term RCTs contribute to the broader evidence landscape by characterizing the measured activity under the specific conditions of the trials. The evidence contributes to understanding symptom patterns in conditions involving acute and disruptive episodes.

What remains uncertain is the applicability of these findings to long-term pain management. The research has been limited by short follow-up durations, as treatment with Nam is restricted to a maximum of 15 consecutive days. This means that long-term effects are not fully established, and there is limited information for long-term outcomes beyond this brief treatment window.

---

Evidence for Use in Primary Dysmenorrhoea

Research explored the conditions characterized by fluctuating or episodic manifestations like primary dysmenorrhoea (menstrual discomfort). Research examined patients experiencing outcomes describing episodic or acute changes in pain related to their menstrual cycle. Studies were conducted during periods of increased symptom activity and were primarily Short-term Randomized Controlled Trials.

Data for certain groups remain insufficient, as the research is restricted to primary dysmenorrhoea, and there is limited information for secondary dysmenorrhoea (pain caused by another underlying condition). Furthermore, the follow-up durations were limited to the acute symptomatic phase, providing restricted insight into any potential long-term use patterns.

Common questions about Nam (FAQ)

---

Q: What is the main medical condition Nam is officially approved to treat?

According to regulatory documents, Nam (Nimesulide) is approved for the symptomatic treatment of acute pain and the symptoms associated with osteoarthritis and primary dysmenorrhoea (menstrual discomfort). Official labeling states the drug is indicated for adults and adolescents over 12 years of age and is restricted to short-term use.

---

Q: Is a slight headache a frequent or common side effect listed for Nam?

Official safety information includes headache and dizziness among the reported side effects. Dizziness, for example, is classified in some regulatory labeling as an uncommon to rare reaction.

---

Q: Are there any reported delayed or long-term side effects associated with Nam use?

Regulatory documents limit the duration of systemic use to a maximum of 15 consecutive days. Because of this limitation, the official research evidence states that long-term effects are not fully established beyond this brief treatment window.

---

Q: Does Nam interact with common over-the-counter pain relievers like acetaminophen or ibuprofen?

Nam is an NSAID, and regulatory guidance notes that using it alongside other pain relievers may increase the risk of side effects. Official warnings advise caution regarding combination with other medicines that may affect the liver due to the potential for compounded risk.

---

Q: How long does it typically take for a person to notice the effects of Nam?

Official product information indicates that the onset of action for the oral tablet or granules is typically documented as 2 to 3 hours after administration. This represents the approximate period before the medicine is documented to begin its effect.

---

Q: What is the official guidance on using Nam during pregnancy or while breastfeeding?

Use of Nam during the third trimester of pregnancy is formally contraindicated in regulatory documents. Use during the first and second trimesters, as well as while breastfeeding, is generally not recommended; official guidelines state that use requires careful consideration of the risks versus benefits.

---

Q: Are there specific laboratory tests or monitoring required for patients using Nam?

Due to the documented risk of liver toxicity, regulatory guidance recommends regular monitoring of liver function (including liver enzymes), especially if treatment is prolonged. Also, official information states that individuals using Nam concurrently with warfarin may need close monitoring of their INR (blood clotting level).

---

Q: Does Nam carry a special safety warning or 'Boxed Warning'?

In some regulatory environments, authorities have mandated a mandatory 'Box Warning' to draw attention to the serious risk of liver toxicity (hepatotoxicity). This warning also highlights the restrictions placed on the maximum duration of use.

---

Q: What is the general expectation for improvement when using Nam?

The general purpose of Nam, as stated in regulatory materials, is to provide symptomatic relief for acute physical discomfort. Research evidence is structured around monitoring the time until a measurable change in pain level is reported by patients.

---

Q: Are there any known occupational or environmental hazards related to Nam?

Official disposal guidance requires that unused product not be released into the environment, including preventing disposal into sewers or public waters. Occupational guidelines recommend using suitable gloves and caution for handling with open cuts or abraded skin.

---

Q: What is the difference between Nam and other medicines in the same treatment class?

Nam is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its official pharmacological designation is a preferential Cyclooxygenase-2 (COX-2) inhibitor, which is the specific action profile that distinguishes its mechanism from traditional non-selective NSAIDs.

---

Q: Is Nam considered a first-line treatment option for its primary indication?

According to some regulatory environments, Nam is restricted to second-line therapy for patients over 12 years old. This means that regulatory status suggests its use may be reserved for cases where first-line treatment options are not suitable.

---

Q: Does Nam work similarly to any older, established medications?

As a drug classified as an NSAID, Nam achieves its effects by suppressing pro-inflammatory signals through the inhibition of the Cyclooxygenase enzyme. This foundational mechanism is similar to many older pain relievers, but Nam specifically targets the COX-2 enzyme.

---

Q: What is the official guidance regarding Nam's potential to cause weight changes?

Official safety information notes that Nam can cause fluid retention in some individuals. This may potentially lead to edema (swelling) and associated weight gain as a reported adverse effect.

---

Q: Can Nam affect a person's sleep patterns or cause insomnia?

Adverse effects reported on the nervous system include somnolence (drowsiness) and nervousness. These effects are listed in official product information and may influence sleep patterns.

---

Q: What are the documented signs of an allergic reaction to Nam?

Documented signs of a hypersensitivity reaction can include reactions like skin rash, itching, swelling, dizziness, and difficulty breathing. Severe reactions, such as Stevens-Johnson Syndrome, are also classified in the regulatory materials.

---

Q: What is the general advice about consuming alcohol while a person is using Nam?

General safety warnings advise caution regarding alcohol consumption. Using Nam with alcohol may potentially worsen central nervous system side effects like drowsiness and may add to the already documented risk of liver toxicity.

---

Q: Are there any specific foods or drinks that should be avoided when taking Nam?

One regulatory SmPC states that Nam has no known interaction with general food and drinks. However, official instructions specify that the oral dose should be taken after a meal to ensure proper administration.

---

Q: How does Nam interact with common supplements like St. John's wort or herbal products?

Drug interaction resources indicate that Nam is linked to certain drug metabolism pathways. Supplements like St. John's wort are known to affect these pathways, which could potentially reduce the effectiveness of Nam or other co-administered medications.

---

Q: Does Nam affect the efficacy of birth control pills?

Drug interaction resources have linked Nam to hormonal contraceptives. Furthermore, supplements documented to interact with Nam have also been noted to reduce the effectiveness of hormonal contraceptives in general.

---

Q: How long does the body typically take to clear Nam after the last dose?

Based on pharmacokinetic data, the half-life of Nam (Nimesulide) typically ranges from 2 to 5 hours. The half-life describes the time required for the body to clear half of the active substance from the bloodstream.

---

Q: Is Nam currently available as a generic medicine?

Official product information confirms that Nimesulide is available in the form of capsules and granules for oral suspension in both generic and trade formulations in markets where it is approved by regulators.

---

Q: Is Nam classified as a controlled substance in the country's drug schedules?

Nam is classified as a prescription-only medicine in most markets where it is available. Official government drug resources do not generally list it as a controlled substance in major drug schedules.

---

Q: Where can a user find the official prescribing information or patient leaflet for Nam?

The official prescribing information is contained in the Summary of Product Characteristics (SmPC) in Europe or the equivalent Prescribing Information/Labeling filed with the governing regulatory authority in the country of use. This document contains all mandated details.

---

Q: When was Nam first approved by regulatory agencies like the FDA or EMA?

According to historical drug data, the active ingredient Nimesulide was first introduced into the market in January 1985.

---

Q: Are there any recent safety updates or warnings issued about Nam?

Regulatory agencies have, in some regions, mandated new cautionary labels and restrictions on use due to ongoing concerns about potential liver damage (hepatotoxicity). These updates are generally reflected in the official prescribing information.

---

Q: Is there evidence suggesting Nam can affect a person's ability to drive or operate machinery?

Official warnings advise that Nam may cause central nervous system side effects such as dizziness or blurred vision. Official guidance indicates that individuals who experience these documented effects should avoid driving or operating machinery.

---

Q: Why do official documents mention 'unknown risk' for certain populations using Nam?

This language is used in official documents to denote patient populations or outcomes for which there is insufficient clinical data. This is primarily due to the mandated limited duration of studies (maximum 15 days) and restricted data for specific conditions or patient groups.

---

Q: Is Nam known to cause or worsen anxiety?

The medicine's nervous system side effects include reported instances of nervousness and dizziness. While these are noted in official labeling, the term 'anxiety' itself is not explicitly used as a classified adverse effect.

How to Store and Dispose of Nam (Nimesulide)

The storage of Nam must adhere to strict regulatory conditions to maintain its integrity. Oral formulations of Nimesulide should be stored at temperatures not exceeding 25 C, while the topical gel must be stored not above 30 C. The medicine must be kept in its original container, which must be tightly closed and protected from light and moisture.

All Nimesulide products must be stored out of the sight and reach of children. For disposal, unused or expired product and its container must be handled according to local regulations for medicinal waste. It is mandatory that the medicine not be released into the environment, including preventing disposal into sewers or public waters.